Jove
Visualize
Contact Us

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489
Cancer Vaccines01:30

Cancer Vaccines

345
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
345
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Fanca Promotes Lung Adenocarcinoma Progression And Is A Potential Target For Epitope Vaccine Immunotherapy.
  1. Home
  3. Fanca Promotes Lung Adenocarcinoma Progression And Is A Potential Target For Epitope Vaccine Immunotherapy.

Related Experiment Video

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

16.9K

FANCA promotes lung adenocarcinoma progression and is a potential target for epitope vaccine immunotherapy.

Yanli Kang1,2, Ruifang Zhong1, Yuhan Gan1

  • 1Shengli Clinical Medical College of Fujian Medical University, Fuzhou, China.

Journal of Translational Medicine
|October 7, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Elevated FANCA promotes lung adenocarcinoma (LUAD) malignancy and poor survival. A specific FANCA peptide (SLLEFAQYL) shows promise for developing targeted LUAD immunotherapy.

More Related Videos

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

5.5K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

Related Experiment Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

16.9K
Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

5.5K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Fanconi anemia, complementation group A (FANCA) mutations are implicated in various cancers.
  • The role of FANCA in lung adenocarcinoma (LUAD) occurrence and immune response remains uncharacterized.

Purpose of the Study:

  • To investigate the functional role of FANCA in LUAD progression and its impact on the tumor immune microenvironment.
  • To explore the potential of FANCA-derived peptides as targets for LUAD immunotherapy.

Main Methods:

  • Analysis of FANCA expression and survival data in LUAD using TCGA, TIMER, and PrognoScan databases.
  • In vitro validation of FANCA's role in LUAD cell proliferation, migration, and invasion.
  • Prediction and synthesis of HLA-A2-restricted FANCA antigenic peptides for immunotherapy development.
  • Assessment of peptide-induced cytotoxic T lymphocyte (CTL) activity against LUAD cells.

    • Main Results:

    • High FANCA expression in LUAD correlates with poorer overall survival and advanced clinical stages.
    • FANCA knockdown significantly inhibits LUAD cell proliferation, migration, and invasion.
    • FANCA expression is linked to immune infiltration levels, genomic alterations, and tumor mutational burden (TMB).
    • A synthesized FANCA peptide (SLLEFAQYL) demonstrated enhanced affinity for dendritic cells (DCs) and potent CTL-mediated killing of LUAD cells.

    Conclusions:

    • Elevated FANCA expression promotes malignant phenotypes in LUAD and influences patient prognosis through immune modulation.
    • The FANCA-derived peptide SLLEFAQYL is a potential epitope for developing an effective LUAD vaccine.